Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.
Consensus
Corticosteroid
Halobetasol
Plaque psoriasis
Retinoid
Tazarotene
Topical therapy
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
26
04
2024
accepted:
31
05
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
25
6
2024
Statut:
aheadofprint
Résumé
An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose combination halobetasol propionate (HP)/tazarotene (TAZ) lotion (HP/TAZ) in the treatment algorithm for plaque psoriasis. A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada. The first expert panel session was held to discuss the existing body of literature and develop draft consensus statements about topical therapies and the place in therapy of HP/TAZ. Independent feedback on the draft consensus statements was solicited from expert panel members prior to another expert panel session where the amended consensus statements were further discussed, edited and, finally, voted on. The expert panel reached consensus on 20 statements. Expert panel members agreed, based on the existing body of literature, that there is a place in therapy for HP/TAZ to address several current unmet treatment needs of patients with plaque psoriasis. Studies have shown that HP/TAZ is an effective and safe first-line treatment for moderate-to-severe plaque psoriasis. Due to its cosmetically pleasing vehicle and once-daily administration, HP/TAZ may improve patient acceptance and treatment adherence.
Identifiants
pubmed: 38916719
doi: 10.1007/s13555-024-01204-1
pii: 10.1007/s13555-024-01204-1
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210–9. https://doi.org/10.2310/7750.2011.10066 .
doi: 10.2310/7750.2011.10066
pubmed: 21781627
Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2022;148(1):95–102. https://doi.org/10.1001/archdermatol.2011.1410 .
doi: 10.1001/archdermatol.2011.1410
Papp K, Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg. 2010;14(4):167–74. https://doi.org/10.2310/7750.2010.09066 .
doi: 10.2310/7750.2010.09066
pubmed: 20642985
Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053–64. https://doi.org/10.1007/s13555-021-00518-8 .
doi: 10.1007/s13555-021-00518-8
pubmed: 33886086
Elmets CA, Korman NJ, Prater F, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432–70. https://doi.org/10.1016/j.jaad.2020.07.087 .
doi: 10.1016/j.jaad.2020.07.087
pubmed: 32738429
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–15. https://doi.org/10.1016/S0140-6736(20)32549-6 .
doi: 10.1016/S0140-6736(20)32549-6
pubmed: 33812489
Nicholas MN, Gooderham M. Psoriasis, depression, and suicidality. Skin Ther Lett. 2017;22(3):1–4.
Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535. https://doi.org/10.1136/bmjopen-2018-027535 .
doi: 10.1136/bmjopen-2018-027535
pubmed: 31005939
pmcid: 6500315
Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–113. https://doi.org/10.1016/j.jaad.2018.11.058 .
doi: 10.1016/j.jaad.2018.11.058
pubmed: 30772097
Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–40. https://doi.org/10.1111/j.1365-4632.2011.05359.x .
doi: 10.1111/j.1365-4632.2011.05359.x
pubmed: 23171010
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–5. https://doi.org/10.1001/jamadermatol.2013.5264 .
doi: 10.1001/jamadermatol.2013.5264
pubmed: 23945732
Feldman SR, Goffe BS, Rice G, et al. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–13.
pubmed: 28465778
pmcid: 5394561
Canadian Psoriasis Network. Psoriasis journey to stability. National report—Canadians’ journey living with psoriasis. 2018.:2–31. https://www.canadianpsoriasisnetwork.com/wp-content/uploads/2018/09/JTSFinal-r.pdf . Accessed
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85.
pubmed: 28404701
pmcid: 5389757
Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–93. https://doi.org/10.1016/j.jaad.2018.03.040 .
doi: 10.1016/j.jaad.2018.03.040
pubmed: 29614243
Green L, Armstrong A, Teller CF, Bell S, Lin T. Treatment of psoriasis: a survey on patient preference and satisfaction. Skin J Cut Med. 2020;4(1):S1–S1.
Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1729335 .
doi: 10.1080/09546634.2020.1729335
Maliyar K, Fleming P, Ogunyemi B, Lynde C. A brief history of psoriasis management in Canada. J Cutan Med Surg. 2020;24(3):273–7. https://doi.org/10.1177/1203475420903682 .
doi: 10.1177/1203475420903682
pubmed: 32003582
Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. https://doi.org/10.1155/2012/561018 .
doi: 10.1155/2012/561018
pubmed: 23213332
pmcid: 3508578
Tanghetti E, Lebwohl M, Stein GL. Tazarotene revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy. J Drugs Dermatol. 2018;17(12):1280–7.
pubmed: 30586260
Sugarman JL, Stein Gold L, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A phase 2, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):197–204.
pubmed: 28301614
Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17(8):855–61.
pubmed: 30124724
Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol. 2021;35(5):1152–60. https://doi.org/10.1111/jdv.17113 .
doi: 10.1111/jdv.17113
Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating psoriasis with halobetasol propionate and tazarotene combination: a review of phase II and III clinical trials. Ann Pharmacother. 2020;54(9):872–8. https://doi.org/10.1177/1060028020910439 .
doi: 10.1177/1060028020910439
pubmed: 32126800
Bhatia ND, Pariser DM, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15–9.
pubmed: 30588269
pmcid: 6303116
Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatol Treat. 2019;32(4):391–8. https://doi.org/10.1080/09546634.2019.1668907 .
doi: 10.1080/09546634.2019.1668907
PRDUOBRII™ halobetasol propionate and tazarotene lotion 0.01% w/w halobetasol propionate and 0.045% w/w tazarotene Product monograph including patient medication information Bausch Health, Canada Inc. 2150 St-Elzear Blvd., West Laval, Quebec, H7L 4A8 Canada. June 8, 2020. https://pdf.hres.ca/dpd_pm/00056991.PDF
Black N, Murphy M, Lamping D, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy. 1999;4(4):236–48. https://doi.org/10.1177/135581969900400410 .
doi: 10.1177/135581969900400410
pubmed: 10623041
Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011;25(Suppl. 4):3–8. https://doi.org/10.1111/j.1468-3083.2011.04059.x .
doi: 10.1111/j.1468-3083.2011.04059.x
pubmed: 21507077
Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–5. https://doi.org/10.1016/j.jaad.2018.09.002 .
doi: 10.1016/j.jaad.2018.09.002
pubmed: 30227193
Lebwohl MG, Tanghetti EA, Stein Gold L, Del Rosso JQ, Gilyadov NK, Jacobson A. Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther. 2021;11(4):1157–74. https://doi.org/10.1007/s13555-021-00560-6 .
doi: 10.1007/s13555-021-00560-6
Stein Gold L, Lain E, Green LJ, Lin T, Israel R. Halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol. 2019;18(8):815–20. https://doi.org/10.1016/j.jaad.2019.06.277 .
doi: 10.1016/j.jaad.2019.06.277
Stein Gold L, Kircik LH, Pariser D, et al. Rapid onset of action in patients with moderate-to-severe plaque psoriasis with halobetasol 0.01%/Tazarotene 0.045% fixed combination. J Drugs Dermatol. 2018;17(8):863–8.
pubmed: 30124725
Lebwohl MG, Stein Gold L, Del Rosso JQ, Green L, Jacobson A. Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. J Dermatol Treat. 2021. https://doi.org/10.1080/09546634.2021.1914310 .
doi: 10.1080/09546634.2021.1914310
Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European union: a systematic review of the literature. Patient Prefer Adher. 2016;10:2357–67. https://doi.org/10.2147/PPA.S117006 .
doi: 10.2147/PPA.S117006
Committee C. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med and Surg. 2016;20(5):375–431. https://doi.org/10.1177/1203475416655705 .
doi: 10.1177/1203475416655705
Vender R, Gooderham MJ, Guenther LC, et al. Canadian patients’ preferences in topical psoriasis care: Insights from the PROPEL surveys. J Cutan Med Surg. 2018;22(5):464–71. https://doi.org/10.1177/1203475418773736 .
doi: 10.1177/1203475418773736
pubmed: 29754528
Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–14. https://doi.org/10.1001/archderm.140.4.408 .
doi: 10.1001/archderm.140.4.408
pubmed: 15096368